Novartis Venture Fund — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Aravaxaravax.com.auinJan 2024 · $66M✓ verified
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.
BiotechHealthtechMedical DevicesMelbourne, AU
Sara Prickett(Co-founder)
Co-investorsTenmileBreakthrough VictoriaUniSeed Pty Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.